From Wikipedia, the free encyclopedia
Foretinib
Names
Preferred IUPAC name
N 1 -[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N ′1 -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names
XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
3D model (JSmol )
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.158.129
KEGG
UNII
show Key: CXQHYVUVSFXTMY-UHFFFAOYSA-N
InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
show COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Properties
Chemical formula
C 34 H 34 F 2 N 4 O 6
Molar mass
−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Chemical compound
Foretinib is an experimental drug candidate for the treatment of cancer.[1] Exelixis and is under development by GlaxoSmithKline .[2] [3] [4]
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[5]
See also [ ] c-Met inhibitors Cabozantinib , a similar molecule and kinase inhibitor with FDA approvalVEGFR inhibitor tyrosine-kinase inhibitor References [ ]
^ Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs of the Future . 35 (11): 893–901. doi :10.1358/dof.2010.35.11.1529012 (inactive 31 May 2021). CS1 maint: DOI inactive as of May 2021 (link ) ^ "XL880 (GSK1363089)" . Exelixis, Inc.^ "Foretinib" . clinicaltrials.gov.^ "Foretinib - AdisInsight" . adisinsight.springer.com . Retrieved 16 April 2018 .^ Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J; et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research . 69 (20): 8009–16. doi :10.1158/0008-5472.CAN-08-4889 . PMID 19808973 .
show Angiopoietin
Antagonists: Angiopoietin 2 Kinase inhibitors: Rebastinib Antibodies: Evinacumab (against angiopoietin 3)Nesvacumab (against angiopoietin 2) CNTF EGF (ErbB)
FGF
FGFR1 FGFR2
Agonists: FGF (1 , 2 (bFGF) , 3 , 4 , 5 , 6 , 7 (KGF ), 8 , 9 , 10 (KGF2) , 17 , 18 , 22 )Palifermin Selpercatinib Sprifermin Trafermin FGFR3 FGFR4 Unsorted
HGF (c-Met)
Agonists : Hepatocyte growth factor IGF
LNGF (p75NTR )
Antagonists: Dexamethasone Testosterone PDGF RET (GFL)
SCF (c-Kit) TGFβ Trk
TrkA
Antagonists: Dexamethasone FX007 Testosterone Negative allosteric modulators: TrkB TrkC
VEGF
Decoy receptors: Aflibercept Others
Additional growth factors: Adrenomedullin Colony-stimulating factors (see here instead)Connective tissue growth factor (CTGF) Ephrins (A1 , A2 , A3 , A4 , A5 , B1 , B2 , B3 )Erythropoietin (see here instead)Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF) Glia maturation factor (GMF) Hepatoma-derived growth factor (HDGF) Interleukins /T-cell growth factors (see here instead)Leukemia inhibitory factor (LIF) Macrophage-stimulating protein (MSP; HLP, HGFLP) Midkine (NEGF2) Migration-stimulating factor (MSF; PRG4) Oncomodulin Pituitary adenylate cyclase-activating peptide (PACAP) Pleiotrophin Renalase Thrombopoietin (see here instead)Wnt signaling proteins Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
Categories :
Tyrosine kinase inhibitors Quinolines Morpholines Cyclopropanes Fluoroarenes Abandoned drugs Hidden categories:
CS1 maint: DOI inactive as of May 2021 Chembox CAS registry number linked ECHA InfoCard ID from Wikidata Pages using collapsible list with both background and text-align in titlestyle Articles containing unverified chemical infoboxes Chembox image size set Articles with short description Short description matches Wikidata Articles containing potentially dated statements from October 2015 All articles containing potentially dated statements
